

The background of the slide features a series of overlapping, flowing waves in shades of blue and green, creating a sense of movement and depth. The waves are more pronounced on the left side and fade towards the right.

rameda

AGENDA

- 01. Financial Results
- 02. Stock Information
- 03. Company Overview
- 04. Market Dynamics
- 05. Ramedia Value Drivers
& Tailwinds
- 06. Management Guidance
- 07. Appendix






.01 Financial Results


Financial Highlights



2Q 2025 Financial Highlights



1H 2025 Financial Highlights






.02

Stock Information

Rameda is the Only Non-State-Owned Listed Pharmaceutical Entity on the EGX30

	Revenue	EBITDA	Net Income	Implied EV/EBITDA	Share Price
2024 Analyst Median Consensus ¹	EGP 2,737	EGP 777	EGP 382	9.6x (2024A)	Analyst Consensus EGP 7.4 65% vs. August Share Price
2024 Actual Results	EGP 2,769 1.2% vs. Analyst Consensus	EGP 807 3.9% vs. Analyst Consensus	EGP 402 5.2% vs. Analyst Consensus	9.2x (2024A)	
2025 Analyst Median Consensus ¹	EGP 4,305	EGP 1,333	EGP 651	5.1x (2025E)	



(1) Consensus Includes EFG Hermes, CI Capital, Beltone, HSBC, Mubasher and Rumble
(2) As of June 2025






.03

Company Overview

Building on Strong Momentum to Become Egypt's leading Pharma Player

Rameda has high growth potential in each of its business lines, and demonstrates strong operational performance



Market Dynamics and Rameda's Key Value Drivers

Market Dynamics



Large, High Growth Private Pharma Market

(2nd largest in MENA region)

EGP 215 bn¹, with 23.4% 4Y CAGR



Local Manufacturers Outgrowing Multinationals

23% vs. 18% 5-Year CAGR



Regulatory-Driven Product Price Adjustments

Gross margin recovery

Rameda's Value Drivers & Tailwinds



Unique Acquisition Strategy

42 acquisitions since 2012



Growing Higher Quality Chronic Segment

Double digit increase YoY



Building Cosmeceuticals and Nutraceuticals

Increasing revenue contribution to 20%+ target



Correction of Mispriced Products

~20% of revenue repriced



Volume Recovery

Overcoming Temporary Setbacks



Grow Accretive Contract Manufacturing

Lowers unit costs & generates revenue



Hedging USD Exposure through Exports

Active in Egypt's largest export pharma markets

(1) Only includes private sales, which account for ~66% of total market





.04 *Market Dynamics*


Industry Tailwind: Large, High Growth Pharma Market

Egypt's pharmaceutical market demonstrates consistently attractive growth




Annual Pharmacy Sales Value (IQVIA) | EGP bn

23.4% 4-Year CAGR




Monthly Pharmacy Sales Value Evolution (IQVIA) | EGP bn

■ 2023 ■ 2024




Industry Tailwind: Local Manufacturers Outperform Multinationals with Competitive Pricing & Availability


Locals (generics) Outgrowing Multinationals and Capturing Increasing Market Share




Local Generics Replacing Innovators (Multinationals) Products



Local vs. Multinationals Pharmacy Sales | % (IQVIA)



Industry Tailwind: Regulatory-Driven Product Price Increases



Egyptian Drug Authority (EDA) Announces Price Increase Approvals for several Products

11th of August 2024, Cairo, Egypt

“The EDA, which governs the prices of drugs in the local market, allowed, in May 2024, pharmaceutical companies operating in the local market to increase select drug prices by around 30 percent for chronic disease medications, 40 percent for acute disease medication, and 50 percent for OTC medications”




Egypt's Ministry of Health Product (MOHP's)
Pricing Committee

Pharmaceutical product prices are regulated by the
MOH transparently and supportively

↓
EGP / USD
-15%



Product upward
re-pricing



Products Repricing
Drives contribution margins recovery post
currency depreciation


Rameda 2024 Average Price Adjustment
c. 50%



Industry Tailwind: Supportive Pricing Regime

Egypt Benefits from a Favorable Regulatory Environment Most Evident in a Supportive and Transparent Pricing Regime

If EGP/USD rate fluctuates by 15%/annum, the MOHP will adjust market prices to maintain margins



2016/17

A price increase of 20% was applied to all products priced at under EGP301. A price increase of 50% was applied to 15% of Ramedia

2022

Ramedia received approval for price hikes between 20-30% for products that represent 90% of the Group's revenues

2023

Ramedia's top 15 selling products witnessed various waves of price increases and represented 70% of the Group's sales in FY23

2024

Products accounting for 90% of Ramedia's portfolio received price increases averaging 40%-50%.

Distinctive Pricing Structure Set by Regulator Benefits Local Generic Manufacturers

Regulations Limit the Number of Competitors per Molecule

First-to-market submissions enable higher sales and margins versus peers

~75% of Ramedia's revenue is generated by new products introduced through acquisitions or new launches

New products = Higher prices = Higher margins





.05

Rameda Value Drivers & Tailwinds

Revenue Driver: Unique acquisition strategy

Molecule (Market Authorization) Acquisitions Proven to be a Superior Growth Strategy



Rameda cherry-picks molecules in attractive therapeutics areas and with superior margin profiles compared to Rameda's portfolio

42

Acquisitions since 2012


EGP 1.1bn

Spent on Acquisitions since 2012
(EGP 470mn of which in 2024)

Valuation Arbitrage

Highly Value-Accretive

Revenue Contribution (EGP mn)




Accretive Acquisitions – New Acquisitions in 2024 to Contribute 9% of 2025 Sales

Rameda Completes Largest Acquisition to Date, Acquiring the Leading Product in the Newer-Generation Oral Anti-Diabetics Market, Becoming a Top Player in Chronic Care

Rank: 1st
In Units Sold

(Newer-Generation Oral Anti-Diabetics Market)



Indication



Vildagliptin and metformin are used to treat adult patients with type 2 diabetes. This type of diabetes is also known as non- insulin-dependent diabetes mellitus.

Market Highlights



The product automatically enters Rameda's top 3 products and has the potential to generate around 9% of Rameda's annual sales in 2025, with an acquisition value of EGP 470mn.

New Generation Oral Anti-Diabetics
Market

EGP 6.7 bn

New Generation Oral Anti-Diabetics
Market 3-Year CAGR (value)¹

43%

Sugarlo 3-Year CAGR (value)¹

60%

Sugarlo Gross Profit Margin

+70%

Full Impact of Sugarlo Acquisition will Become Evident In 2025 Results

(1) Source IQVIA As of MAT August 2024



Revenue Driver: Growing Higher Quality Chronic Segment


Shifting Our Portfolio Toward High-growth, Sticky Chronic Segments that Drive Sustainable, High Margin Revenue




Strategic Opportunities in Chronic Care

Growing Demand	Increasing awareness in a growing market
Patient Compliance	Product compliance drive recurring revenues
High Unit Margin	Segment's Products Naturally Command Higher Margins

Portfolio Mix 2023



Portfolio Mix 2024



Rameda’s strategic realignment enabled through targeted acquisitions and a deliberate focus on this segment for new product launches




Strategic Expansion – Through Product Launches

Driving Future Growth with a Robust Pipeline



Building on our commitment to both high-quality chronic care and expanding our freely priced portfolio, we are strategically growing our product offerings through carefully planned and executed launches



Launching a new product is a long-term commitment, the process from API acquisition to market entry typically spans 18 to 24 months. This timeframe underscores the need for strategic planning and forward-thinking in our product development efforts.



Revenue Driver: Building Cosmeceuticals and Nutraceuticals verticals

Recent Focus on Cosmetics, Nutraceuticals and Medical Devices



- High Margin Contribution (Superior to existing margin profile)
- Under-Penetrated, Fragmented Market Segment
- Freely-Priced products
- High Growth Market with Lower Export Restrictions





Revenue Driver: Correction of mispriced products




Adjust Historical Pricing Distortions

Effective regulatory engagement to level product pricing with leading peers




Augram

96% Upward Repricing



Rametax

64% Upward Repricing



Rameceftrax


61% Upward Repricing

Full Impact of Rameda’s Product Repricing Will Become Evident In 2025 Results





Revenue Driver: Volume Recovery

Rameda's core volume growth trajectory will be further boosted as these temporary setbacks subside




FX Availability & Supply Chain

Currency depreciation caused supply chain issues, reducing lower-margin product output



FX stability and resolution of supply chain issues driving volume recovery in a key products




Market Reaction to Product Misuse

Misadministration of an injectable antibiotic led to market confusion and volume decline



Physician-backed awareness efforts restored confidence our injectable antibiotics, driving volume recovery



Cost Optimization: Growing Accretive Contract Manufacturing

Well-Invested, Large Manufacturing Facilities



USD 0mn

Growth CAPEX Required ⁽¹⁾



Certified Facility

3 Factories
20 Production Lines

Broad Manufacturing Capabilities

Diversified

Dosage Forms

Immediate Term Opportunity to Generate Accretive Revenue through Leveraging Rameda’s Contract Manufacturing (CM) Services



Contract
Manufacturing
Services

Reduced Unit
Costs of
Production


Increased Utilization Drives
Average Lower Unit Costs
of Production

Revenue
Potential

Utilizing Available Capacity
unlocks revenue at
negligible associated costs

Bottom-Line
Growth

Lower average unit costs
and new accretive revenue
boost net profit growth



(1) The facility is well-invested For approximately 5 years




Cost Optimization: Hedging USD Exposure through Exports

Unlocking market growth & FX Resilience, with a double-digit target export revenue contribution



Geographical Presence



Management focus and guidance

Export Revenue: 8 – 10% of Total

Current Export Revenue = ~30% of Imported Materials Cost

Revenue Diversification and FX Capture

Reduced reliance on local economic fluctuations

Increases FX inflows, enhancing financial resilience

Regulatory Expertise

Regulatory Strength = Faster Market Entry

Quick Approvals & Seamless Commercialization

Active in 7 Markets, Expanding to 15+ in the Medium Term



Resulting in outperformance in active Strategic Therapeutic Areas (TAs)

- 1

Consistent Outperformance

Rameda outgrows the market in nearly all therapeutic areas
- 2


Attractive Therapeutic Areas

Focused on high-value, high-growth and high margin TAs
- 3

Balanced & Resilient Portfolio

Diversified across multiple therapeutic areas

Rameda's Exposure to Therapeutic Areas in 2024 (IQVIA)





.06

Management Guidance

Management Guidance

		FY24A	FY25E
Revenue		EGP 2.6bn	EGP 4.2 - 4.5 bn (+60-75% yoy)
GP Margin		46%	48-52%
SG&A Margin		20%	17-22%
EBITDA Margin		29%	30+%
Debt	Net Debt / EBITDA	1.6x	1.0x – 1.5x
Cash Conversion Cycle	Number of days	215 days	≈
Net Income Growth	Percentage growth in net income	59%	+25-35%

Assumes a fixed exchange rate of 51 USD/EGP throughout the period

Assumes an average inflation rate of 25%

Excludes any impact of potential price increases

Excludes potential acquisitions & revenues from Glow






.07 Appendix

High Prevalence of Chronic Conditions



Egypt's Addressable Population with Respective Chronic Conditions (mn) | Prevalence as % of Population



Egypt's epidemiological profile continues to evolve in a manner consistent with underlying demographic trends, with a growing prevalence of chronic and lifestyle diseases such as diabetes, hypertension and depressive disorder.

Government initiatives, such as the Universal Healthcare Law and Nationwide screening program have boosted the detection and diagnosis rate for noncommunicable diseases while increasing patient access to adequate treatment.

Sources: Business Monitor, Euromonitor, IMS  No. of Rameda's marketed products for each disorder



Rameda's Core Values

Driving Our Success: Mission, Vision, & Purpose

Rameda is a leading Egyptian pharmaceutical company that develops and produces a wide range of branded generic pharmaceuticals, nutraceuticals, food supplements and veterinary products.



Vision

To become the most
valuable emerging
pharmaceutical company in
Egypt



Mission

To be the primary choice
for doctors, pharmacists,
and consumers.




Purpose

To provide customers with
healthcare solutions that
better their quality of life.




Our Evolution




Pharma Market Overview

Based on 2024 sales, Rameda ranks #14 by value and is the fastest-growing among the top 15, with a 38% CAGR from 2020-2024, surpassing the market's 26% CAGR.





Based on units sold, Rameda ranks #10 and is the second fastest-growing company, achieving a 14% CAGR compared to the market's 1%




Key Player in the Pharmaceutical Industry

In 2024, Rameda has delivered outstanding results in terms of volume growth, achieving 23% YoY growth, far exceeding the market's average of +1%.



Defined Private Market Performance | FY24

Benchmarked against its peers with similar portfolio compositions (ATC4 Markets), Rameda ranks 4th in terms of size (by value). In 3-year CAGR terms, Rameda outpaced the defined market's growth by 6.7 percentage points, achieving a CAGR of 33.4% in FY24.



Total Defined Private Market Performance (FY24)		
+48.5%	+26.7%	93.1 bn
YoY Growth	3-Year CAGR	2024 Value




Product Price Increases Supporting Growth and Profitability – 2024

Products Accounting for Over 90% of the Group's Revenue Have Undergone an Average Price Adjustment Of c. 50%. Since the End of May, Price Increase Approvals Were Gradually Granted to the Company



In Addition to Standard Price Approvals, Rameda Secured Special Repricing for Key Products Augram, Rametax, and Rameceftrax, Achieving Price Increases of Up to 96%



Note: Price increase percentages are calculated as the new price divided by the original base price

The Group’s price increases across its products have played a pivotal role in boosting revenue growth as well as supporting the health of Rameda’s profitability margins amidst challenging market conditions and Rameda is looking to generate increased value from upcoming price increase approvals over the coming periods

Average Price Increase
c.50%




Highly Accretive Acquisitions Validate Strategy

Recent Acquisitions Overview




Product Sales (In EGP Millions)



81%	EGP 93
GPM	2024 Average selling price




Product Sales (In EGP Millions)



51%	EGP 89
GPM	2024 Average selling price



Product Sales (In EGP Millions)



91%	EGP 262
GPM	2024 Average selling price



Launches/Acquisitions of Freely-Priced Products to Contribute 5-10% of 2025 Revenue

The company is strategically focusing on cosmetics, nutraceutical and medical devices to capitalize on an under penetrated, high growth and profitability market

Physiomer



Acquired in 2022, Physiomer is a natural decongestant nasal spray that provides relief from nasal conditions by helping to clean nasal passages.

Physiomer is a natural decongestant nasal spray that provides relief from nasal conditions.

According to IQVIA, growth in the overall market for the molecule delivered a 2019-21 CAGR of 16% and boasts an overall market size of c.EGP 221 million.

250
Price / Pack

Ramelact




Launched in 2024, Ramelact is the first lactase enzyme specifically designed for adults in

Egypt, addressing the issue of lactose intolerance, which affects a staggering 68% of Egyptians. Ramelact is now available over the counter in pharmacies across Egypt, offering an accessible solution for lactose intolerance.

Priced at EGP 360 for 30 tablets, this launch supports Rameda's strategy to expand its freely priced product offerings.

350
Price / Pack

Bellavie




We have successfully registered 6 Bellavie products and obtained their licenses for imported bulk. These products will be packaged in carton boxes at our Rameda facility in Egypt. Sales are anticipated to begin in 2025.

450
Price / Pack



Glow –A Strategic Expansion into the Thriving Freely Priced Cosmetics & Cosmeceutical Market

Glow: Rameda’s Cosmeceutical Arm



Board Structure



Ayman Abbas
Chairman, Non-executive Director

- Founder and Chairman of ADES, a leading Egyptian company operating in oil and gas services. ADES is listed on the London Stock Exchange
- Vice Chairman of Intro Group, a multi-disciplinary organisation where he founded leading companies in multiple industries including oil and gas exploration, oil services, real estate, construction and IT
- Abbas holds a B.A. in Business Administration from the American University in Cairo



Shamel Aboul Fadl
Non-executive Vice Chairman, Shareholder Representative

- Aboul Fadl has over 3 decades of experience in financial services, focusing on the buy-side
- Chairman of Equinox Pharma Holding Company
- Chairman of Compass Capital, a leading financial services firm established in 2010. The firm boasts experience in a multitude of industries such as pharmaceuticals, financial services, oil & gas, real estate, telecom, FMCG and construction
- Previously Managing Partner at Pharos Holding, where he grew the company to a leading full-fledged investment bank
- Previously CEO of Paragon Asset Management in Switzerland and Vice President at Citigroup in Switzerland
- Prior to that, Aboul Fadl was Vice President at Mansour and Maghraby Investment and Development, responsible for Private Equity investments.
- Aboul Fadl holds a B.Sc. In Construction Engineering from the American University in Cairo, and an MBA from Wharton Business School



Dr. Amr Morsy
Chief Executive Officer, Executive Director

- Dr. Morsy has 30 years of experience that covers strategic and operational expertise in the Pharmaceutical industry. Dr. Morsy brings to Rameda a wide range of experience in finance, business planning and strategy, human resources, product development and sales & marketing
- Prior to joining Rameda, Dr. Morsy was the Country Manager of Pfizer Egypt and Sudan, which he joined in 1995. Prior to this he was Area Sales Manager for Middle & Eastern Provinces at Schering-Plough in Saudi Arabia
- Dr. Morsy holds a B.Sc. of Pharmacy degree from Alexandria University an MBA from Arab Academy for Science and Technology, Alexandria. Dr. Morsy has also participated in the Pfizer Leadership Development Program, Harvard Business School



Mahmoud Fayek
Chief Financial Officer, Executive Director

- Mr. Fayek previously held various positions at Compass Capital, including Vice President in the company's private equity team and member of the board of directors
- At Compass Capital, Mr. Fayek played an integral role in the completion of several transactions across the pharmaceutical, financial services and real estate sectors and conducted various secondments with the Group
- Prior to joining Compass Capital, Mr. Fayek held several senior positions including CFO and Business Development in the manufacturing business
- Mr. Fayek is Chartered Financial Analyst (CFA) charter-holder with significant experience in the financial sector and holds a Bachelor Degree in Business Administration from the Arab Academy for Science, Technology and Maritime Transport



Dr. Mohamed Farouk
Non-executive Director, Shareholder Representative

- Dr. Farouk is the Chief Executive Officer of ADES, a leading Egyptian company operating in oil and gas services and listed on the London Stock Exchange
- Dr. Farouk brings a wealth of experience as he has founded and led companies across different sectors including telecommunications, advanced engineering software outsourcing, and oil exploration and production
- Dr. Farouk holds a Bachelor of Science and a Master of Science in Electric Engineering from Cairo University and a Ph.D. in Systems Engineering and Control from Case Western Reserve University in Ohio, USA



Board Structure



Tarek Abdelrahman
Non-executive
Director, Shareholder
Representative

- Mr. Abdelrahman is the Managing Director of Compass Capital. He was previously the Chief Operating Officer of Palm Hills for Development, one of the largest real estate companies in Egypt. During his time at Palm Hills, he led the company back to profitability and increased net profits by four times as well as recapitalising the company through raising USD 550mn through debt and equity
- Prior to that, he was the Founding Partner and Managing Director of Akanar Partners, an Egyptian advisory firm which was acquired by Arqaam Capital. During his time there, he led and closed transactions for over USD 150mn
- He has also held previous positions in Beltone Investment Banking, Citigroup, EFG Hermes and HSBC Cairo. Mr. Abdelrahman holds a B.A. in Business Administration from the American University in Cairo and an MBA Degree from London Business School



Karim Zahran
Non-executive
Director, Shareholder
Representative

- Mr. Zahran is the Chief Executive Officer of Zahran Market, a leading supermarket retail chain, malls and distributor of household goods. He spearheaded the restructuring and positioning of Zahran in the Egyptian market
- Mr Zahran has held roles in HSBC Securities in New York where he focused on US based hedge funds and mutual funds investing in the EMEA region. He has also held previous roles in ACE Group and Citigroup Private Bank in Geneva
- Mr. Zahran holds a Bachelor of Science in Business Administration with a concentration in Finance and a B.A. in Economics from Boston University



Mohamed Gamal El Shoura
Non-executive
Director, Shareholder
Representative

- Mr. El Shoura holds the role of Deputy Chief Investment Officer at Ekuity Holding, the investment arm of the Kuwait Investment Authority in Egypt (The Kuwaiti Sovereign Wealth Fund).
- He brings over 17 years of extensive experience in private equity, investment management, and has taken lead on multiple M&A transactions and turnarounds in the healthcare and pharmaceuticals sectors, tourism and hospitality, as well as the food and beverage space.
- Mr. El Shoura holds a bachelor's degree in Commerce from Cairo University, in addition to several professional certificates in feasibility studies and M&As from the Faculty of Economics and Political Science at Cairo University and London Business School (LBS).



Hatem Soliman
Independent Non-
Executive Director

- Mr. Soliman spent 37 years with Schlumberger after joining in 1982 as a graduate electrical engineer. His longstanding career with Schlumberger included senior roles in the Middle East, Europe, Latin America and the Caribbean
- From 2010 to 2016, Mr. Soliman held the position of President of Schlumberger Latin America, before taking on the role of President of Schlumberger Middle East and Asia
- Before his retirement from Schlumberger in October 2018, Mr. Soliman was appointed as a Senior Advisor to Schlumberger's global CEO



Mirna Arif
Independent Non-
Executive Director

- Mirna Arif is the General Manager of Microsoft Egypt and boasts over 20 years of experience leading digital transformation strategies for multinational and public sector entities across Europe, the Middle East and Africa.
- Prior to becoming Microsoft Egypt's General Manager in 2020, Arif was Microsoft's Surface Business Group Director for Middle East and Africa at their Dubai-based office, and also held the role of Regional Director for Digital Transformation at GE Oil and Gas, where she was responsible for leading and overseeing their digital transformation strategy in North Africa and Turkey.
- Arif holds an MBA from the American University in Cairo (AUC) and a Bachelor of Science in Computer Science from AUC.



Executive Management



Dr. Amr Morsy
Chief Executive
Officer

- Dr. Morsy has 30 years of experience that covers strategic and operational expertise in the Pharmaceutical industry. Dr. Morsy brings to Rameda a wide range of experience in finance, business planning and strategy, human resources, product development and sales & marketing
- Prior to joining Rameda, Dr. Morsy was the Country Manager of Pfizer Egypt and Sudan, which he joined in 1995. Prior to this he was Area Sales Manager for Middle & Eastern Provinces at Schering-Plough in Saudi Arabia
- Dr. Morsy holds a B.Sc. of Pharmacy degree from Alexandria University an MBA from Arab Academy for Science and Technology, Alexandria. Dr. Morsy has also participated in the Pfizer Leadership Development Program, Harvard Business School



Mahmoud Fayek
Chief Financial
Officer, Executive
Director

- Mr. Fayek previously held various positions at Compass Capital, including Vice President in the company's private equity team and member of the board of directors
- At Compass Capital, Mr. Fayek played an integral role in the completion of several transactions across the pharmaceutical, financial services and real estate sectors and conducted various secondments with the Group
- Prior to joining Compass Capital, Mr. Fayek held several senior positions including CFO and Business Development in the manufacturing business
- Mr. Fayek is Chartered Financial Analyst (CFA) charter-holder with significant experience in the financial sector and holds a Bachelor Degree in Business Administration from the Arab Academy for Science, Technology and Maritime Transport



Khaled Daader
Head of IR & M&A

- Mr. Daader held the position of Head of Investor Relations at Juhayna, where he worked for 7 years with experience in Finance, Export, Planning and Strategy and Investments.
- Prior to that, he was part of CI Capital's investment banking team, completing several transactions across the hospitality, real estate, consumer and education sectors.



Najla Muttawa
Human Resources
Director

- Ms. Muttawa brings substantial HR expertise from various roles and industries, including Human Resources Director at General Motors and Gourmet.
- She is also a seasoned trainer, having designed and delivered training programs in banking, pharmaceuticals, oil & gas, and hospitality in Egypt and across the world.
- Ms. Muttawa holds a Bachelor degree in Business Administration and a Masters degree in Education from the American University of Cairo.



Mohamed Aboamira
Finance Director

- Mohamed has been at Rameda since 2012, starting initially as Treasury Manager where he was responsible for cash management, risk assessment and financial analysis
- Prior to that, he held various positions as a financial auditor in a leading audit firm, where he had experience for 8 years



Executive Management



Abdallah Negm
Business Technology
Director

- Eng. Abdallah Negm is the Group's Business Technology Director and boasts over 17 years of experience across the information technology space, including digital transformation strategy, IT budgeting, cybersecurity, artificial intelligence, and analytics.
- Prior to joining Rameda, he spent 15 years at General Motors Egypt and North Africa, where he held various roles, including IT Operations Manager and IT Operations Team Lead. Eng. Negm holds a bachelor's degree in computer science and is a member of the Institute of Electrical and Electronics Engineers.



Dr. Amgad Elgabri
Chief Commercial
Officer

- Dr. Elgabri held the position of National Sales Manager at UCP & MEC where he was overseeing the sales of Pfizer products, leading nationwide sales team members to achieve sales targets
- Prior to that he held numerous positions at Bristol Myers Squibb where he started as a Medical Representative and gained extensive sales experience to eventually become Area Sales Manager



Dr. Rania Farouk
Medical Director

- Dr. Farouk is an associate professor of Oral Medicine at the Modern Sciences and Arts University, where she has spent more than 24 years as a faculty member
- Since 2019, she has overseen the Faculty of Dentistry's research committee. Further, she served as the head of the faculty's educational programs development
- Dr. Rania graduated from the Faculty of Dentistry at Cairo University and has since written several publications for a variety of reputed scientific journals.



Mohamed Hafez
Audit, Risk Mgmt &
Compliance Manager

- Mohamed Hafez currently serves as Senior Manager of Internal Audit, Risk & Compliance.
- He brings over 19 years of experience spanning internal audit, compliance, risk management, accounting, and financial control.
- Before joining Rameda, Mohamed spent 14 years at Orange Egypt, where he advanced through multiple leadership roles across finance, internal control, and audit. He is a Certified Risk Management Professional (CRMP) accredited by Egypt's Financial Regulatory Authority (FRA).



Dr. Ossama Heiba
Site Director

- Ossama Heiba joined Rameda in 2025 as Site Director, bringing over 35 years of extensive pharmaceutical industry experience in Egypt and the wider MENA region.
- Prior to joining Rameda, Ossama held senior leadership roles including Site Director at Sedico and at Pharco, as well as Production Manager and Deputy Plant Manager at Tabuk Pharmaceuticals in Saudi Arabia.
- Ossama holds a B.Sc. in Chemistry (1985) and an M.Sc. in Chemistry (1996) and is currently completing a Master's in Law (2025).





rameda